anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To effectively use stem and leaf of Curcuma domestica of a plant of the genus Curcuma as unused resources containing a large amount of useful components expected to have an antioxidative function and a pharmacological effect and to obtain a raw material for a medicine, a quasi medicine and a health food for a specific health insurance, or the like, from the purified substance of the stem and leaf. SOLUTION: Currently, stem and leaf of plant Curcuma domestica is allowed to stand up to a harvesting time and is dumped at the time of harvesting of rhizome. The stem and leaf contains a large amount of useful components expected to have a pharmacological effect, needless to say, an antioxidative function so that the unused resources are effectively used by this invention. Since the stem and leaf as raw materials are harvested plural times a year, the optimum harvesting time for minimizing the influence on the reproduction of the stem and leaf is elucidated, and the stem and leaf are harvested. The stem and leaf have the mutually same components in offensive smell, sharp taste, bitterness, or the like, a those of rhizome.  The objective product is obtained by processes such as vacuum drying, low- temperature sterilization, or the like, including a continuous fermentation with plural bacteria, as a method for deodorization, removal and reduction in the components and increasing the additional value of the contained components.
Disclosed are Gongjindan (a medicinal herb pellet ball) with minimized loss of active ingredients and a method for manufacturing the same. Gongjindan comprises: a inner core comprising a mixture of musk, elecampane, Aquilaria agallocha roxburgh, deer antlers, and a first sub-material; and an outer layer comprising Korean angelica root, deer antlers, Cornus officinalis and a second sub-material. Gongjindan is manufactured by making the outer layer cover the inner core. A user can easily and visually check a state that musk, elecampane, Aquilaria agallocha roxburgh, and deer antlers are contained in Gonjindan. Therefore, user satisfaction is increased. Gonjindan can have increased efficiency of distribution and storage as effects of musk, elecampane, and Aquilaria agallocha roxburgh which are aromatic medicine materials are maintained for a long period of time.
Depression in adolescents and young adults is a prevalent illness in Canada and presents a high burden for those affected and their families. In Canada, depressive disorders are on the rise and their onset is occurring earlier in life. There is a growing body of evidence suggesting that spiritual wellness may play a role in depression management and recovery. Considering the limitations of available treatments for depression and the significant burden of the disease there is a need for new treatment options that are safe, effective, affordable and acceptable to young people. Our previous research gives strong support to the idea of using a spiritually based intervention for depression. To our knowledge, no research has been conducted on using spirituality as a self-study intervention in the management of depression in young adults. Over the last two years our team has created a spirituality-based intervention program for adolescent depression. The program could present an innovative and low cost treatment option for young patients with major depression.
Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer-associated mortality, with a rising global incidence. A paucity of strong predictive risk factors mean screening programmes are difficult to implement. Historically, a lack of identifiable and actionable driver mutations, coupled with a relatively immunosuppressed tumour microenvironment, has led to a reliance on cytotoxic chemotherapy. The NAPOLI-3 trial has reported data supporting consideration of NALIRIFOX as a new first-line standard of care. Kirsten Rat Sarcoma Virus (KRAS) G12D mutations are present in >90% of all PDAC's; exciting breakthroughs in small molecule inhibitors targeting KRAS G12D may open new modalities of treatment, and therapies targeting multiple KRAS mutations are also in early clinical trials. Although immunotherapy strategies to date have been disappointing, combination with chemotherapy and/or small molecule inhibitors hold promise and warrant further exploration.
TAFINLAR Monotherapy (Adult): In the pooled safety population [see Adverse Reactions (6.1)], uveitis occurred in 1% of patients.

TAFINLAR Administered with Trametinib (Adult): In the pooled safety population [see Adverse Reactions (6.1)], uveitis occurred in 2% of patients.

TAFINLAR Administered with Trametinib (Pediatric): In the pooled safety population, uveitis occurred in 1.2% of patients.

Treatment employed in clinical trials included steroid and mydriatic ophthalmic drops. Monitor patients for visual signs and symptoms of uveitis (e.g., change in vision, photophobia, eye pain). If iritis is diagnosed, administer ocular therapy and continue TAFINLAR without dose modification. If severe uveitis (i.e., iridocyclitis) or if mild or moderate uveitis does not respond to ocular therapy, withhold TAFINLAR and treat as clinically indicated. Resume TAFINLAR at the same or lower dose if improves to Grade 0 or 1. Permanently discontinue TAFINLAR for persistent Grade 2 or greater uveitis of > 6 weeks [see Dosage and Administration (2.4)].
The present invention relates to a traditional Chinese medicine preparation for treating acute pharyngitis and chronic pharyngitis and a preparing method thereof. The traditional Chinese medicine preparation is formed by preparing native achyranthes, roughhaired holly root and radix glycyrrhiza according to certain weight proportioning. The traditional Chinese medicine has the functions of clearing heat, detoxicating, relieving the throat to restore voice, promoting salivation, eliminating vexation, dispersing accumulation and dissolving stagnation. In particular, the present invention is suitable for treating swelling and pain in the throat caused by exuberant lung and stomach. The traditional Chinese preparation of the present invention has the functions of relieving fever and relieving pain, and has the pharmacological action on the prevention of inflammation. The present invention both can be used for treating acute pharyngitis and can also be used for treating chronic pharyngitis.
Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
Application of Continuous Positive Upper Airway Pressure (CPAP) during sleep using nasal mask is the gold standard treatment for Obstructive Sleep Apnea (OSA). In clinical practice, many patients with OSA are considered mouth breathers and use an oronasal mask. However, CPAP delivered by the mouth violates the principal of CPAP use to treat OSA. This study is part of a line of research over the last decade that started with the observation of a patient that CPAP delivered by an oronasal mask failed to splint the airway open and to abolish OSA . We showed subsequently in acute studies during induced-sleep that oronasal CPAP only works when the patient breathes predominantly through the nose. These observations prompted our group to lead one workshop on the importance of mask selection. One meta-analysis from our group confirmed that oronasal CPAP is associated with a higher CPAP level, higher residual AHI, and poorer adherence than nasal CPAP. Despite all this evidence the investigators intrigued by the clinical observation that oronasal masks remains common and several patients on clinical practice are well adapted to oronasal CPAP. In this study, 20 patients with OSA well adapted to the oronasal mask will be recruited. The patients will be invited to be submitted to 2 independent CPAP titration sleep studies using a customized oronasal mask with a sealed and independent nasal and oral compartments coupled to 2 pneumotachographs. One CPAP titration will be with the nasal and oral routes open and one CPAP titration with only the oral compartment opened. Our hypotheses are that obstruction of nasal compartment during CPAP titration causuing mouth breathing will result in higher CPAP and higher residual apnea-hypopnea index. Patients with OSA under treatment with oronasal CPAP will undergo CPAP titration polysomnography on 2 different nights. In one night the patient will sleep with the oral and nasal compartments opened and in another night interposed by at least seven days, the patient with sleep with only the oral compartment opened. The order of the 2 sleep studies will be randomized. Thus, researchers will assess the impact of the airway (oral vs oronasal) on titrated CPAP level, residual AHI, and sleep efficiency in supine and lateral recumbency. In addition, the preferred airway during the oronasal mask will be analyzed. At the end of the study a nasal mask will be offered to all patients.
PURPOSE: A device for manufacturing soft gelatin capsules is provided to prevent a gelatin sheet from being adhered to the surface of a wedge and a molding roller. CONSTITUTION: A device for manufacturing soft gelatin capsules comprises a main body(10), a sheet drum(50), a molding roller(40), a wedge(30) discharging liquid medicine, and an elevating device. The sheet drum is arranged in both sides of the main body and forms gelatin sheet. An actuating rod performs backward stroke in power failure. When the actuating rod performs backward stroke, the wedge is separated from the gelatin sheet. The elevating device is equipped with an actuator, a pipe, and a control unit.
People who are part of a dimensionally-organized psychosis sample spanning several serious mental illness diagnoses including schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder. Eligible participants will be scheduled for two dose visits where they will receive a 600mg CBD dose on one day and a placebo dose on the other day. Doses will be randomized and double-blind. Doses will be administered via oral gel capsules.
Psoriasis is a chronic, proliferative, and inflammatory skin disease closely associated with inflammatory cytokine production. Cyclophilin A (CypA) is an important proinflammatory factor; however, its role in psoriasis remains unclear. The present data indicate that CypA levels are increased in the lesion skin and serum of patients with psoriasis, which is positively correlated with the psoriasis area severity index. Furthermore, extracellular CypA (eCypA) triggered psoriasis-like inflammatory responses in keratinocytes. Moreover, anti-CypA mAb significantly reduced pathological injury, keratinocyte proliferation, cytokine expression in imiquimod-induced mice. Notably, the therapeutic effect of anti-CypA mAb was better than that of the clinically used anti-IL-17A mAb and methotrexate. Mechanistically, eCypA binds to ACE2 and CD147 and is blocked by anti-CypA mAb. eCypA not only induces the dimerization and phosphorylation of ACE2 to trigger the JAK1/STAT3 signaling pathway for cytokine expression but also interacts with CD147 to promote PI3K/AKT/mTOR signaling-mediated keratinocyte proliferation. These findings demonstrate that the binding of eCypA to ACE2 and CD147 cooperatively triggers psoriasis-like inflammation and anti-CypA mAb is a promising candidate for the treatment of psoriasis.
Cytosolic double-stranded DNA (dsDNA) is frequently accumulated in cancer cells due to chromosomal instability or exogenous stimulation. Cyclic GMP-AMP synthase (cGAS) acts as a cytosolic DNA sensor, which is activated upon binding to dsDNA to synthesize the crucial second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP) that in turn triggers stimulator of interferon genes (STING) signaling. The canonical role of cGAS-cGAMP-STING pathway is essential for innate immunity and viral defense. Recent emerging evidence indicates that 2'3'-cGAMP plays an important role in cancer progression via cell autonomous and non-autonomous mechanisms. Beyond its role as an intracellular messenger to activate STING signaling in tumor cells, 2'3'-cGAMP also serves as an immunotransmitter produced by cancer cells to modulate the functions of non-tumor cells especially immune cells in the tumor microenvironment by activating STING signaling. In this review, we summarize the synthesis, transmission, and degradation of 2'3'-cGAMP as well as the dual functions of 2'3'-cGAMP in a STING-dependent manner. Additionally, we discuss the potential therapeutic strategies that harness the cGAMP-mediated antitumor response for cancer therapy.
6 patients were included in this split-mouth RCT. In control sites a horizontal GBR procedure was performed using a titanium reinforced dPTFE membrane with a graft consisting of 50% autogenous bone and 50% DBBM. In test sites a titanium reinforced dPTFE membrane was used, with a graft consisting of an LPRF block. This was left to heal for 9 months. Subsequently an implant was placed. At time of implant placement a bone biopsy was taken. After 4 months of osseointegration the abutment connection was performed. 1 year after loading of the implants a final check was done. CBCT scans were taken at intake, immediately after reconstruction, 9 months after reconstruction, before implant placement and 1 year after loading of the implants.

Primary outcome measure is the bone volume as measured on the CBCT scans. Secondary outcome measures are bone quality in the biopsy, buccal bone thickness around the oral implant, number and type of complications, cumulative survival rates of the implants 1 year after loading.
The invention provides compositions and methods for treating human papillomavirus (HPV) comprising a ribonucleoprotein (RNP) comprising a RNA-guided nuclease and an RNA with a portion complementary to a target site within a viral nucleic acid of said virus. The composition comprises a targetable nuclease selected from the CRISPR associated protein and Cpf1 or Cas9 and a nuclear localization signal, further comprising a liposome. The target site lies within an E6 or E7 gene of the HPV genome and the composition may comprise a first and second RNP enveloped in a first and second liposome wherein the second target site lies within E6 or E7. The invention further relates to a composition comprising a vector encoding the RNP further comprising a tissue specific promoter for a keratinocyte. Other nucleases may also be used selected from zinc finger nuclease (ZFN), a transcription activator like effector nuclease (TALEN) and a meganuclease. The composition may further comprise a carrier for topical application to skin.
We plan on injecting a tube into healthy fed pigs (eg. Omega 3; Antioxidants) pigs' and/or cows' and/or elephants' and/or any large easy to impregnate and frequent pregnancies to drain some of the flow of amniotic fluid from the umbilical chord/placenta to create tissue culture medium for stem cells of any type.   We are also looking at taking DNA from the cells in the gonads of a healthy adult and apply electricity into an Oocyte with its nucleus removed and follow regular tissue culture stem cell/cloning procedures.   Furthermore we could take the stem cells that continue to proliferate the longest and micro inject their DNA into female Oocytes and apply electricity...   Re: All Animals; eg. pigs, cows, elephants, rhinos, alligator/crocodile, sturgeon, Boa Constrictor/Anaconda/Python, Tigers, Lions, Mountain Lions, (crickets, locusts - easy to multiply in very short period of time, pigeons, chickens, Lama, Emu, Ostriches, Caribou, Moose, Deer, Elks, Whales, Sharks... We want either larger cells or more cell proliferations to be used as food source or feeder layer for cloning eg. human stem cells, or used for in vitro;  in vivo cloning a specimen with desirable phenotypes.   We are also trying to use different levels of LIF (leukemia inhibitory factor) to trigger STAT 3.  As well we are experimenting the gene POU5f1 gene that encodes the Oct - 4.     We plan separate the and replate the colonies to form single wells.   Additionally we will experiment with basic fibroblast growth factor (bFGF) and forsklin.  We also plan as stated in our past patents use telomerase enzymes (such as [1, 36]).  Furthermore:   1. We could take the cells that are still undifferentiated and continuing to proliferate and replating to start new colonies. 2. We could combine this with our own patented method/technique of taking stems cells that have finished proliferation and re injecting their DNA(s) into mass numbers Oocyte (with their nucleus removed).
Hypoxia (low oxygen) causes the blood vessels in the lungs to constrict (hypoxic pulmonary vasoconstriction). This increases the pressure (afterload) the right ventricle faces as it pumps blood to the lungs. Increased right ventricular afterload during hypoxia may compromise exercise capacity. Intravenous iron administration prior to hypoxic exposure has been shown to blunt the hypoxia-induced increase in right ventricular afterload. This may be through iron's action in the Hypoxia Inducible Factor (HIF) pathway. Iron is a cofactor for prolyl hydroxylases that degrade HIF subunits and thus may "turn off" HIF-related pathways of pulmonary artery vasoconstriction and remodeling. However, it is not known whether oral iron supplementation similarly reduces right ventricular afterload in hypoxia, or what impact iron has on right ventricular function and exercise capacity in hypoxia.

This is a human physiology study that will characterize the impact of oral iron supplementation on right ventricular function and exercise performance in hypoxia. It is a follow-up "sub-study" to a separate, "parent" study (NCT05272514) by the same investigators which evaluates resting and exertional right ventricular performance in normoxia and hypoxia in 10 healthy individuals. In this follow-up study, 5 individuals who completed the parent study will be eligible to enroll. As part of the parent study, participants will complete baseline echocardiography to assess right ventricular function and cardiopulmonary exercise testing to assess exercise performance in normoxia and hypoxia. After enrolling in this study, participants will take an oral iron supplement (ferrous sulfate 325 mg oral daily) for 30 days. They will then return for one visit. First, participants will complete submaximal exercise while breathing room air. Submaximal exercise will include 5 minutes each at 40% and 60% of baseline hypoxic (fraction of inspired oxygen \[FiO2\] 12%) maximal oxygen uptake (VO2max) achieved during parent study. After 10 minutes' rest, echocardiographic measurements will be obtained at upright rest with FiO2 21%, 17%, 15%, and 12% to characterize the impact of progressive hypoxia on resting right ventricular function. Participants will then repeat submaximal exercise tests at FiO2 12%, followed by a short period of recovery. Thereafter, participants will complete a symptom-limited cardiopulmonary exercise test at FiO2 12%. Measurements will include heart rate/rhythm, oxygen saturation, blood pressure, gas exchange parameters (oxygen uptake \[VO2\], carbon dioxide production \[VCO2\], and minute ventilation), rated perceived exertion and resting echocardiographic measurements.
BACKGROUND/OBJECTIVES: Glucagon-like peptide-1 agonists (GLP1As) are increasingly prescribed to treat obesity. While studies document how these medications impact dietary habits, their relationship to consumer food waste is unexplored. Approximately one-third of all food is wasted, which creates substantial economic and environmental damage. The purpose of this study is to assess how consumers alter food waste after beginning GLP1As and to identify factors associated with this relationship.
METHODS: Retrospectively reported changes in the amount of food wasted since beginning a GLP1A are gathered from a sample of 505 U.S. consumers via a self-administered online survey. Regression analysis yields associations between changes in post-GLP1A-uptake food waste and the length and type of medication use, medication side effects, post-uptake changes in dietary habits, and respondent characteristics.
RESULTS: A total of 25% of respondents agree they waste more food since beginning the medication, while 61% disagree. Respondents are significantly less likely to agree with this statement if they have been on the medication a longer time and are significantly more likely to agree if they reported experiencing nausea since beginning the medication. Dietary changes consistent with more vegetable intake are also significantly associated with less waste.
CONCLUSIONS: Uptake of a novel class of anti-obesity medications may significantly affect food waste patterns. With the potential for widespread adoption of such medications, and given the societal import of reducing food waste, understanding the interaction of these two consumer trends is critical for projecting their joint impact on the food system and for equipping new GLP1A users to limit food waste.
INTRODUCTION: Peptic ulcer disease (PUD) and postprocedural artificial ulcers are common ulcer disease. For them, proton pump inhibitor (PPI) and potassium-competitive acid blocker (P-CAB) are commonly used in clinical practice. PPI requires acid, time, and multiple doses, but P-CAB has fewer limitations. We compared the efficacy, safety, and prevention of PPI and P-CAB in PUD or artificial ulcer.
METHODS: We searched PubMed, ClinicalTrials.gov , Embase, Cochrane Library, and Web of Science databases for all studies. All eligible randomized controlled trials up to August 5, 2023, were included. Healing rates, shrinking rates, treatment-emergent adverse events rates, and recurrence rates were measured. Risk of bias, sensitivity analyses, and heterogeneity were also performed.
RESULTS: Twenty researches that were selected from 926 screening studies and in total 6,551 participants were included. The risk ratio (RR) of healing rate with P-CABs vs PPIs of PUD at 4 weeks was RR 1.01 (95% confidence interval 0.98-1.04). In addition, the healing rate distinction of artificial peptic ulcer was RR 1.04 (0.89-1.22), and the shrinking rate was mean difference 0.10 (-1.30-1.51). The result of treatment-emergent adverse event rate of PUD was RR 1.11 (0.91-1.35), and the delayed bleeding rate of artificial ulcer was RR 0.35 (0.16-0.80). The RR for recurrence rate of drug-related ulcers was 0.45 (0.25-0.81).
DISCUSSION: P-CAB is noninferior in healing artificial ulcer and PUD, also the incidence of treatment-emergent adverse events. But, there may be a statistical advantage in holding back delayed bleeding and preventing drug-induced ulcers. More standardized experiments are needed for further applications and more precise conclusions.
PROBLEM TO BE SOLVED: To provide the above raw material composed of a specific fatty acid ester (or its condensate) or a methylpolysiloxane, having repelling or non- attracting action on mites such as American house dust mite or European house dust mite and useful for cosmetics, pharmaceuticals, etc., for the treatment of atopic dermatitis. SOLUTION: The objective base contains an 8-18C branched fatty acid (poly) glyceryl ester (e.g. glyceryl triisostearate), an 8-12C straight-chain fatty acid glyceryl ester (e.g. glyceryl tricaprate), an oxystearic acid or an 8-18C branched fatty acid ester of pentaerythritol or dipentaerythritol (e.g. dipentaerythritol hexaoxystearate), an 8-18C branched fatty acid ester of isononyl alcohol (e.g. isononyl isononanate), a methylpolysiloxane containing 10-100 methylsiloxane units or a condensation product of a 4-8C dibasic acid and an 8-18C branched fatty acid ester of a polyhydric alcohol (e.g. glycerol 2-ethylhexanoate adipic acid condensate).